STANDARD REVIEW FORM FOR NATIONAL DEPLOYMENT AND VACCINATION PLAN FOR COVID-19 VACCINES (NDVP)

29 January 2021
COUNTRY:

REVIEWER 1 NAME: REVIEWER 1 AGENCY/AFFILIATION:

REVIEWER 2 NAME: REVIEWER 2 AGENCY/AFFILIATION:
REVIEWER 3 NAME: REVIEWER 3 AGENCY/AFFILIATION:

DATE REVIEW STARTED:

DATE REVIEW COMPLETED:
DATE ONTO COVID-19 PARTNERS
PLATFORM:

If the plan outlines any particular assumptions, highlight them briefy here (e.g. vaccine schedule, product characteristics, duration of plan, other)
ENTER TEXT HERE
 STANDARD REVIEW FORM: NATIONAL DEPLOYMENT AND VACCINATION PLAN FOR COVID-19 VACCINES (NDVP)
29 January 2021

COUNTRY: Enter country name here

Mark with an "X" in the appropriate column

Do not
*Question marked in RED are considered absolute minimal know or
requirements* Yes Partially No cannot
assess Comments or recommendations (if questions are marked "partially" or "no", please
SECTION provide remarks)

1a. Does the plan describe emergency or expedited regulatory

pathways for approval of COVID-19 vaccines?

1b. Do the emergency or expedited regulatory pathways meet at

least one of the three objectives below?

1b1. An exceptional waiver from the appropriate

authority (e.g. head of NRA, executive head of the
government) to use the particular vaccine
Regulatory preparedness

1b2.National regulations providing special provisions for

when a vaccine product is considered automatically
approved by NRA (e.g WHO prequalified, WHO
Emergency Use Listing, or third country regulatory
authority)

1b3. A short/fast-track process for emergency approval

1c. Have barriers or restrictions for issuing an import permit for

the specific product been adequately addressed (by legislation or
executive order)?

1d. Is there confirmation that local testing of the product is not

required prior to introduction?

2a. Does the national coordination mechanism described in the

plan adequately meet coordination requirements anticipated for
COVID-19 vaccine introduction?
 2b. Does the plan clearly describe the highest priority
categories targeted for vaccination, for up to 3% of the
population?

2c. Does the plan provide a clear rationale and criteria for the
prioritization of the first categories to be vaccinated, for up to
3% of the population?

2d. Does the plan adequately describe the delivery strategy for
reaching the highest priority categories to be vaccinated (e.g.
venue and modality of delivery) for up to 3% of the population?

2e. Were the highest priority categories targeted for

Planning, coordination and service delivery

vaccination for at least up to 3% of the population

recommended by the NITAG, other national technical advisory
group or equivalent body?

2f. Does the plan clearly describe the expanded categories

targeted for vaccination beyond the initial 3% (3.1% to 20%) of
the population?

2g. Does the plan provide a clear rationale and criteria for
prioritizing the subsequent 3.1% to 20% of the population for
vaccination?

2h. Does the plan adequately describe the delivery strategy for
reaching beyond the initial 3% (3.1% to 20%) of the population
by venue and modality of delivery?

2i. Were the expanded 3.1 to 20% of the population targeted for
vaccination recommended by the NITAG, other technical
advisory group or equivalent body?

2j. If applicable, does the plan include reference to vaccinating

the highest priority categories targeted for vaccination among
special populations in need of humanitarian assistance such as
refugees, internally displaced persons or others?

2k. Does the plan adequately describe the infection, prevention

and control (IPC) measures established to prevent the spread of
SARS-CoV-2, specifically during vaccination sessions?

3a. Is the plan accompanied by cost estimates and a reasonable

budget for planned activities?
Costing and funding
 Costing and funding
3b. Are funding sources clearly described, including secured
funding sources?

3c. Are budget gaps identified?

3d. Does the plan describe a strategy to address the budget

gaps identified?

4a. Has a cold chain assessment or WHO-UNICEF Effective

Vaccine Management (EVM) assessment been conducted in the
past 12 months?

4b. Is there a clear description of cold chain adequacy at

different administrative levels that will enable vaccine
deployment to the above target groups (refer to 2b, 2f)?

+2 to +8 °C (if applicable)
Supply chain and waste management

-20 °C (if applicable)

-70 °C (if applicable)

4c. Does the plan adddress whether there are adequate

numbers of trained staff for cold chain management and vaccine
handling for COVID-19 vaccine deployment?

4d. Does the plan adequately describe secure distribution and

logistics requirements for each stage of vaccine deployment?

4e. Does the plan adequately describe steps to fill -- prior to

deployment -- any of the gaps potentially identified in the areas
below?
Cold chain equipment
Human resources for cold chain management
Secure distribution and logistics

4f. Does the plan adequately describe the safe handling of waste
management?
Human resources

5a. Does the plan adequately outline how to address the human
and training

resource implications of supporting COVID-19 vaccine

deployment?

5b. Does the plan adequately describe the HR training and

supervision plan?

6a. Does the plan adequately describe a demand generation and

generation

community engagement plan?

Demand

6b. Does the plan adequately describe a risk communication

strategy (e.g. to respond to misinformation or crisis)?
 7a. Does the plan adequately outline the documented COVID-
19 vaccine pharmacovigilance procedures, processes or tools
for conducting the following activities below?

7a1. AEFI reporting

Vaccine safety

7a2. AEFI investigation

7a3. AEFI causality assessment

7a4. Risk communication and response to serious AEFI

7b. Does the plan refer to approaches for implementing risk

management plans ?

7c. Is the country considering to set up a monitoring and

reporting system of other safety concerns such as adverse events
of special interest (AESI)?

8a. Does the plan adequately describe a mechanism for adapting

registers and reporting forms to record COVID-19 vaccination
doses?
Monitoring and evaluation

8b. If applicable, does the plan adequately describe a mechanism

for providing dates/reminders to vaccinees for follow-up doses?

8c. Does the plan adequately describe the system to monitor and
report the required immunization data as defined in the NDVP
guidance?

8d. Does the plan mention the conduct of a programmatic

evaluation following introduction of COVID-19 vaccines?
surveillance
COVID-19

9a. Does the plan adequately describe a mechanism for adapting

case investigation forms to include COVID-19 vaccination status?

Overall, does the plan provide adequate information that reflects

the country's readiness to receive and deploy vaccines to
vaccinate up to 3% of the population?
Conclusions

Overall, does the plan provide adequate information that reflects

the country's readiness to receive and deploy vaccines to
vaccinate 3.1% to 20% of the population?
 Conclusions
Based on this review, is the NDVP considered satisfactory for the
country to be included in any subsequent vaccine allocation
round without undergoing another regional review?

Reviewer(s) to provide brief justification for assesment conclusion noted above

ENTER TEXT HERE

There will be a final verification check by the global Secretariat of the COVAX Facility before vaccine doses are released and shipped to countries. Reviewers can provide below general or specific recommendations to the country on
which aspects of the plan can be improved before final receipt of doses.
ENTER TEXT HERE

© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

WHO reference number: WHO/2019-nCoV/NDVP/review_forms/2021.1